Surf Therapeutics Secures $6M, Advances Non-Invasive Arthritis Treatment
March 21, 2026, 10:34 pm
Surf Therapeutics, an Austin, Texas biotechnology firm, has raised $6 million in total seed funding. This capital boost supports its innovative non-invasive ultrasound neuromodulation therapy. The company's SUSTAIN platform targets chronic inflammatory diseases, starting with rheumatoid arthritis. Early human studies show promising results, reducing key inflammatory markers without surgery or drugs. Surf Therapeutics aims to revolutionize treatment, offering scalable, at-home solutions for widespread immune-mediated conditions. The funding accelerates clinical development and preparation for crucial pivotal trials. This marks a significant step in medical innovation.
Surf Therapeutics has reached a significant milestone. The Austin-based biotechnology company closed an extended seed funding round. This brings its total capital raised to $6 million. The infusion of funds fuels its pioneering work in non-invasive ultrasound neuromodulation. This technology promises a new era for treating chronic inflammatory diseases.
The company's core innovation is its SUSTAIN platform. It employs non-invasive ultrasound to modulate immune-related pathways. This approach aims to activate the body's natural anti-inflammatory response. It eliminates the need for surgery or implanted hardware. Patients could soon manage their conditions safely from home. This design promotes scalable access to vital therapy.
Recent clinical data validates this groundbreaking approach. Surf Therapeutics announced positive first-in-human study results. This multi-center study included 14 participants with inflammatory arthritis. It was a single-blind, sham-controlled, cross-over investigation. The findings were statistically significant. Key pro-inflammatory cytokines, like TNF-α and IL-6, showed marked reductions. This occurred after repeated ultrasound stimulation. The sham treatment showed no such effect.
Patient safety remains paramount. The company reported no device-related adverse events during the study. This critical outcome underscores the potential of their non-pharmacological method. Surf Therapeutics plans to publish these compelling study data soon. Findings will also be presented at EULAR 2026. This prominent European rheumatology congress offers a global platform.
The company's progress has been swift. Founded in late 2022, Surf Therapeutics rapidly moved from concept to human trials. This efficient trajectory highlights the team's capabilities. It also demonstrates the compelling nature of the technology. Preclinical development preceded the successful human studies.
Surf Therapeutics has already initiated its SUSTAIN early feasibility study. This trial evaluates the investigational ultrasound neuromodulation therapy for rheumatoid arthritis. Rheumatoid arthritis is a debilitating chronic inflammatory disease. The trial is actively enrolling patients. Three clinical sites in the Dallas–Fort Worth area are participating. This localized focus helps streamline patient access and study logistics.
The $6 million seed funding is a culmination of investor confidence. It builds on previous seed rounds. A consortium of prominent investors backed the company. These include SOSV, VVP Ignite, TMC Venture Fund, General Inception, Elderberry Ventures, and Evoce Capital. Angel investors, such as Mir Imran of Rani Therapeutics, also contributed. Their support underscores belief in Surf Therapeutics' vision.
Nishant Doctor leads Surf Therapeutics as CEO. His leadership drives the company's ambitious goals. The team is dedicated to translating complex science into practical solutions. The focus remains on patient benefit and widespread accessibility.
Chronic inflammatory diseases affect millions globally. Current treatments often involve complex regimens. They can carry significant side effects. Many require frequent clinic visits or costly pharmaceuticals. Surf Therapeutics' technology offers a compelling alternative. A non-invasive, drug-free, at-home therapy could transform patient care. It could significantly improve quality of life.
The newly raised capital is critical. It will expand the clinical evidence base. It will prepare the company for a future pivotal trial. This large-scale trial is essential for regulatory approval. The ultimate goal is a commercially scalable device. This device will provide at-home treatment for chronic inflammatory conditions.
This represents more than just a funding announcement. It signifies a potential paradigm shift in medicine. Non-invasive neuromodulation holds immense promise. It targets the root causes of inflammation. It does so without systemic drug exposure. This minimizes potential adverse reactions. The vision for at-home use ensures greater patient autonomy. It also reduces healthcare burdens.
Surf Therapeutics is not merely developing a product. It is crafting a new treatment philosophy. One that empowers patients. One that leverages the body's intrinsic healing mechanisms. The medical community eagerly anticipates further data. The journey from initial concept to commercial availability is challenging. Surf Therapeutics has made remarkable strides. Its future looks bright. This innovative company leads the charge. It redefines therapy for inflammatory disease.
Surf Therapeutics has reached a significant milestone. The Austin-based biotechnology company closed an extended seed funding round. This brings its total capital raised to $6 million. The infusion of funds fuels its pioneering work in non-invasive ultrasound neuromodulation. This technology promises a new era for treating chronic inflammatory diseases.
The company's core innovation is its SUSTAIN platform. It employs non-invasive ultrasound to modulate immune-related pathways. This approach aims to activate the body's natural anti-inflammatory response. It eliminates the need for surgery or implanted hardware. Patients could soon manage their conditions safely from home. This design promotes scalable access to vital therapy.
Recent clinical data validates this groundbreaking approach. Surf Therapeutics announced positive first-in-human study results. This multi-center study included 14 participants with inflammatory arthritis. It was a single-blind, sham-controlled, cross-over investigation. The findings were statistically significant. Key pro-inflammatory cytokines, like TNF-α and IL-6, showed marked reductions. This occurred after repeated ultrasound stimulation. The sham treatment showed no such effect.
Patient safety remains paramount. The company reported no device-related adverse events during the study. This critical outcome underscores the potential of their non-pharmacological method. Surf Therapeutics plans to publish these compelling study data soon. Findings will also be presented at EULAR 2026. This prominent European rheumatology congress offers a global platform.
The company's progress has been swift. Founded in late 2022, Surf Therapeutics rapidly moved from concept to human trials. This efficient trajectory highlights the team's capabilities. It also demonstrates the compelling nature of the technology. Preclinical development preceded the successful human studies.
Surf Therapeutics has already initiated its SUSTAIN early feasibility study. This trial evaluates the investigational ultrasound neuromodulation therapy for rheumatoid arthritis. Rheumatoid arthritis is a debilitating chronic inflammatory disease. The trial is actively enrolling patients. Three clinical sites in the Dallas–Fort Worth area are participating. This localized focus helps streamline patient access and study logistics.
The $6 million seed funding is a culmination of investor confidence. It builds on previous seed rounds. A consortium of prominent investors backed the company. These include SOSV, VVP Ignite, TMC Venture Fund, General Inception, Elderberry Ventures, and Evoce Capital. Angel investors, such as Mir Imran of Rani Therapeutics, also contributed. Their support underscores belief in Surf Therapeutics' vision.
Nishant Doctor leads Surf Therapeutics as CEO. His leadership drives the company's ambitious goals. The team is dedicated to translating complex science into practical solutions. The focus remains on patient benefit and widespread accessibility.
Chronic inflammatory diseases affect millions globally. Current treatments often involve complex regimens. They can carry significant side effects. Many require frequent clinic visits or costly pharmaceuticals. Surf Therapeutics' technology offers a compelling alternative. A non-invasive, drug-free, at-home therapy could transform patient care. It could significantly improve quality of life.
The newly raised capital is critical. It will expand the clinical evidence base. It will prepare the company for a future pivotal trial. This large-scale trial is essential for regulatory approval. The ultimate goal is a commercially scalable device. This device will provide at-home treatment for chronic inflammatory conditions.
This represents more than just a funding announcement. It signifies a potential paradigm shift in medicine. Non-invasive neuromodulation holds immense promise. It targets the root causes of inflammation. It does so without systemic drug exposure. This minimizes potential adverse reactions. The vision for at-home use ensures greater patient autonomy. It also reduces healthcare burdens.
Surf Therapeutics is not merely developing a product. It is crafting a new treatment philosophy. One that empowers patients. One that leverages the body's intrinsic healing mechanisms. The medical community eagerly anticipates further data. The journey from initial concept to commercial availability is challenging. Surf Therapeutics has made remarkable strides. Its future looks bright. This innovative company leads the charge. It redefines therapy for inflammatory disease.